Exagen Inc. · NASDAQ:XGN
Exagen — Q3 2026 Earnings Presentation
30 slides from Exagen's earnings presentation, Nov 10, 2026
Slide 1: Q3'26 Financial Results Webcast
Q3’26 Financial Results Webcast John Aballi, President & CEO | Jeff Black, CFO November 10, 2026
Slide 2: Disclaimer
Disclaimer This presentation and all oral statements made by Exagen Inc.’s (“Exagen” or the “Company”) officers, directors or employees in connection with this presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve ris
Slide 3: Q3 & YTD'26 Financial Highlights
Q3 & YTD’26 $18.4M $451 Financial Q3 revenue; Best third quarter in history Q3 AVISE TTM ASP 14th consecutive Q of growth Highlights On track to deliver a record year >11% >30% Revenue growth YTD Adjusted EBITDA growth YTD
Slide 4: Objectives to deliver long-term, profitable growth
4 Objectives to deliver long-term, profitable growth 1 Expand adoption 2 Increase ASP 3 Innovate • Upgrade & expand sales force • Effective RCM & market • Invest in high-potential projects • Support science with evidence access strategies • Regular new product cadence • AI optimized processes • Eval
Slide 5: Adoption is driving AVISE CTD volume growth
5 1 EXPAND ADOPTION Adoption is driving AVISE CTD volume growth Total volume YTD (000s) 1.3M 110 +8% growth YoY YTD AVISE tests since launch 100 45 territories Productivity continues to improve, even with new territories ramping 90 2 of 9 80 Exagen abstracts selected for podium presentation at ACR C
Slide 6: Process optimization fueling continued RCM progress
6 2 INCREASE ASP Process optimization fueling continued RCM progress TTM $ASP* +$10 $460 $451 TTM ASP YoY $440 14th Consecutive quarter of YoY growth $420 $400 >2.5x $380 YoY growth in YTD claims recovered >12 months old 2024 2025 2026 6 | *As of Q3 in each year
Slide 7: Positioning to advance Myositis testing
7 3 INNOVATE Positioning to advance Myositis testing Launch of first new standalone product will leverage established channel >100K U.S. disease prevalence On track for early 2027 launch understates testing opportunity • Rare, but clinically severe autoimmune disease that can Clinical validation com
Slide 8: Exagen Forward: Building the Autoimmune Platform
8 SAVE THE DATE EXAGEN FORWARD Building the Autoimmune Platform December 15 | 12:00pm ET Livestream Further detail coming soon 8
Slide 9: Revenue
FINANCIAL RESULTS Revenue • Adoption and utilization drove Q3’25 Q3’26 YoY YTD’25 YTD’26 YoY volume growth despite seasonality • 6% growth in revenue per territory* Total Revenue $17.2M $18.4M 7% $49.9M $57.7M 11% • RCM contributed to ASP expansion with ~$800K collected on claims Test volume 2% 8% o
Slide 10: Income Statement
FINANCIAL RESULTS Income Statement • Gross margin improvement Q3’25 Q3’26 YoY YTD’25 YTD’26 YoY driven by ASP expansion, operating leverage and ongoing Gross margin % 58.4% 58.8% +40bps 59.3% 59.7% +50bps COGS rationalization Operating expenses $13.2M $15.2M +16% $38.7M $42.8M +11% • Q3 opex include
Slide 11: Opportunistically strengthened balance sheet
FINANCIAL RESULTS Opportunistically strengthened balance sheet Runway to fund business to sustainably positive AEBITDA and operating cash flow • Increased cash by $3.5M in Q3 • Added $6.5M in cash through ATM during Q3 $30M • Drew $5M from expiring $10M $75M tranche under debt facility after Availab
Slide 12: FY 2026 Revenue Outlook
FINANCIAL RESULTS FY 2026 Revenue Outlook Both volume and ASP contributing to growth $72M to $75M • 8% to 13% revenue growth YoY • Volume: High-single digit % growth • ASP: Mid-single digit % growth compared to Q4 2025 exit rate 12 | Guidance as of November 3, 2026
Slide 13: Appendix
EXAGE'N Appendix
Slide 14: Identifying autoimmune disease is a challenge
4 Identifying autoimmune disease is a challenge. Ambiguous symptoms Manifestations overlap Outdated technology Testing delays Tests lack specificity, sensitivity High rate of misdiagnosis 14
Slide 15: Patients spend years seeking answers
15 Patients spend years 6 LUPUS & SJÖGRENS seeking answers. years RHEUMATOID ARTHRITIS & MYOSITIS 15 doctor visits 58 lab procedures 2 years CANCER 4 to 6 months Exagen delivers clarity earlier. 15 | Sources on file. Graphics are not to scale.
Slide 16: Earlier intervention improves outcomes
16 THE PATIENT CHALLENGE Earlier intervention improves outcomes. Lupus Rheumatoid Arthritis 25% Reduction in lupus- related hospitalization1 within first 2 years Inflammation will lead to articular damage & bone erosion without treatment.3 1.5x Reduction in mortality risk related to irreversible org
Slide 17: Conventional biomarkers aren't specific to one disease
THE CLINICAL CHALLENGE Conventional Systemic sclerosis Rheumatoid biomarkers aren’t arthritis specific to one centromere dsDNA ACPA DNA-topoisomerase I histone Sm disease. RNA-topoisomerase III NOR90 nucleosome C1q Fc of IgG Th/To A single autoantibody can carry RNP ribosomal P SSa multiple clinical
Slide 18: Lack of clarity leaves millions without answers
THE CLINICAL CHALLENGE Lack of clarity leaves millions >41M Americans ANA+* without answers. ANA+: antinuclear antibody positive, first-line screen for autoimmune disease ≠ Diagnosed prevalence disease prevalence - between that gap, permanent damage happens Americans ~1.5M diagnosed with lupus* ~1M
Slide 19: AVISE Testing: the simple, clear choice for clinicians
OUR PROPRIETARY SOLUTION 2 tubes of AVISE Testing: patient’s blood the simple, clear choice for clinicians Rheumatologist Exagen lab >1.2M AVISE CTD tests completed Simple | Proven | Trusted AVISE CTD report • Comprehensive panel aids autoimmune disease diagnosis • Proprietary markers • Algorithmic
Slide 20: AVISE outperforms conventional biomarkers
OUR PROPRIETARY SOLUTION AVISE ® Test sensitivity for lupus outperforms 100% conventional 80% biomarkers 80% Conventional markers 66% 60% 44% Better diagnostic accuracy 40% 33% 20% 14% 0% anti-Smith anti-dsDNA C3/C4 CB-CAPs MAP Proprietary markers 20 1. Source: Putterman, et al., Lupus Science and M
Slide 21: AVISE differentiation is earning adoption
AVISE differentiation is earning adoption. Long-tailed opportunity to increase share in a growing market XGN2 Others >$2B 1 # biomarkers on one comprehensive panel 30 15 to 20 ~3% Leading combo of sensitivity & specificity* x U.S. autoimmune diagnostic testing Thresholds set for fewer false positive
Slide 22: Leadership has deep diagnostics expertise
22 Leadership has Chief Executive Officer Chief Financial Officer deep John Aballi Jeff Black diagnostics expertise. Medical & Lab Director Chief Scientific Officer Prashanti Reddy, MD Michael Mahler, PhD BOARD OF DIRECTORS Tina S. Nova PhD Bruce Robertson, PhD Frank Stokes Paul Kim Scott Kahn, PhD
Slide 23: Robust, multi-cohort body of evidence
23 1 ADVANCE ADOPTION Robust, multi-cohort body of evidence 15+ ~50K 3,500+ 12+ peer-reviewed publications patients studied in CAPSTONE clinically characterized subjects rheumatology practices Spanning 2012–2026 Real-world EHR + claims data Multi-center across U.S. In longitudinal utility studies An
Slide 24: AVISE Lupus outperforms conventional biomarkers
OUR SCIENCE AVISE Lupus outperforms conventional biomarkers 1 ® Demonstrated 80% sensitivity | 98% specificity against healthy individuals 100% Test sensitivity for lupus Receiver Operating Curve (ROC) 100% for SLE diagnosis1 80% Conventional markers 80% 66% 60% 60% 44% Sensitivity Sensitivity 40% 3
Slide 25: AVISE CTD test result report
25 OUR SCIENCE AVISE CTD test result report 1 ® Page 1 includes AVISE Lupus and additional SLE biomarkers Pages 2 and 3 contain a comprehensive antibody profile including novel including TC4d and autoantibodies to T Cells anti-RA33 and anti-PAD4 biomarkers Rheumatoid Arthritis Value Interpretation S
Slide 26: Extensive, long-term I.P. protection
OUR SCIENCE Extensive, Patent Families long-term • AVISE: cell-bound complement activation product for I.P. protection diagnosing SLE - 2032 • AVISE : treating & diagnosing likelihood of SLE - 2034 17 • Lupus nephritis biomarkers - 2045 • Use of T-cell autoantibodies + CB-CAPs in diagnosis of SLE -
Slide 27: Demonstrated clinical benefits at scale
EVIDENCE Demonstrated clinical benefits at scale Peer-reviewed Capstone Publication highlights improvements to patient care ~50,000 5.1× 2.8× $985 patient tests analyzed more likely to receive SLE Dx treatment-effect odds avg. annual lab-cost reduction AVISE+ vs. tANA+ (OR 5.11) New patients started
Slide 28: Pipeline prioritizes innovation with impact
3 INNOVATE Pipeline prioritizes innovation with impact Discover Assay developed Algorithmic Clinical validity Reimbursement Commercialized markers to CLIA standards discovery* & utility AVISE CTD expansions: RA33, T-Cell, PAD4 Myositis RA disease activity Lupus Nephritis (urine) Lupus Nephritis (blo
Slide 29: Adjusted EBITDA Reconciliation
Adjusted EBITDA Reconciliation Three Months Ended Nine Months Ended September 30, September 30, 2026 2025 2026 2025 (in thousands) Adjusted EBITDA Net loss $(6,336) $(7,087) $(13,499) $(15,278) Other (income) expense (181) (3) (202) (246) Interest expense 1,201 1,319 3,669 2,988 Loss on extinguishme
Slide 30: Sources
30 Sources Slide # 1. ANA+ prevalence (>41M) Dinse GE, Parks CG, Weinberg CR, et al. Increasing Prevalence 5. Other AVISE CTD autoimmune indications (~1M) of Antinuclear Antibodies in the United States. Arthritis Rheumatol. 2022;74(12):2032–2041. Psoriatic arthritis — CDC. Distribution of Arthritis